Experimental hematology最新文献

Human Pluripotent Stem Cell-Derived Hematopoietic Progenitors and Mature Cells.

IF 2.5 4区医学

Experimental hematology Pub Date : 2025-01-03 DOI: 10.1016/j.exphem.2025.104713

Christopher Sturgeon, Eirini Papapetrou, Shannon McKinney-Fridman

引用次数: 0

The diagnostic and therapeutic potential of multiple myeloma-associated circular RNAs.

IF 2.5 4区医学

Experimental hematology Pub Date : 2025-01-03 DOI: 10.1016/j.exphem.2024.104709

Yue Zhao, Shaokun Wang, Shuang Fu, Xinxin Wang, Jihong Zhang, Fang Chen

{"title":"The diagnostic and therapeutic potential of multiple myeloma-associated circular RNAs.","authors":"Yue Zhao, Shaokun Wang, Shuang Fu, Xinxin Wang, Jihong Zhang, Fang Chen","doi":"10.1016/j.exphem.2024.104709","DOIUrl":"https://doi.org/10.1016/j.exphem.2024.104709","url":null,"abstract":"<p><p>Circular RNA (circRNA) was first discovered in viruses in 1974, they are primarily formed through back-splicing, where a downstream splice donor is joined to an upstream splice acceptor, resulting in a closed circRNA transcript. Under normal conditions, most circRNAs are stably expressed, however, in pathological conditions, circRNAs can play critical roles in the disease process of multiple myeloma (MM) through mechanisms such as competing endogenous RNAs (ceRNAs), regulation of transcription and splicing, affecting protein expression and localization, and even direct encoding of peptides. In recent years, there has been increasing interest in the role of circRNAs in MM and their regulatory functions during the disease process. Numerous studies have revealed that circRNAs are involved in the pathogenesis and prognosis of MM, aiding in the identification of reliable prognostic markers and potential therapeutic targets. Therefore, this review summarizes the structural characteristics of circRNAs, and their regulatory roles in MM, and introduces the latest advancements in understanding the novel functions of circRNAs in MM.</p>","PeriodicalId":12202,"journal":{"name":"Experimental hematology","volume":" ","pages":"104709"},"PeriodicalIF":2.5,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reconsidering the usual suspects in age-related hematologic disorders: is stem cell dysfunction a root cause of aging?

IF 2.5 4区医学

Experimental hematology Pub Date : 2024-12-24 DOI: 10.1016/j.exphem.2024.104698

Foteini Fotopoulou, Esther Rodriguez-Correa, Charles Dussiau, Michael D Milsom

{"title":"Reconsidering the usual suspects in age-related hematologic disorders: is stem cell dysfunction a root cause of aging?","authors":"Foteini Fotopoulou, Esther Rodriguez-Correa, Charles Dussiau, Michael D Milsom","doi":"10.1016/j.exphem.2024.104698","DOIUrl":"https://doi.org/10.1016/j.exphem.2024.104698","url":null,"abstract":"<p><p>Aging exerts a profound impact on the hematopoietic system, leading to increased susceptibility to infections, autoimmune diseases, chronic inflammation, anemia, thrombotic events, and hematologic malignancies. Within the field of experimental hematology, the functional decline of hematopoietic stem cells (HSCs) is often regarded as a primary driver of age-related hematologic conditions. However, aging is clearly a complex multifaceted process involving not only HSCs but also mature blood cells and their interactions with other tissues. This review reappraises an HSC-centric view of hematopoietic aging by exploring how the entire hematopoietic hierarchy, from stem cells to mature cells, contributes to age-related disorders. It highlights the decline of both innate and adaptive immunity, leading to increased susceptibility to infections and cancer, and the rise of autoimmunity as peripheral immune cells undergo aging-induced changes. It explores the concept of \"inflammaging,\" where persistent, low-grade inflammation driven by old immune cells creates a cycle of tissue damage and disease. Additionally, this review delves into the roles of inflammation and homeostatic regulation in age-related conditions such as thrombotic events and anemia, arguing that these issues arise from broader dysfunctions rather than stemming from HSC functional attrition alone. In summary, this review highlights the importance of taking a holistic approach to studying hematopoietic aging and its related pathologies. By looking beyond just stem cells and considering the full spectrum of age-associated changes, one can better capture the complexity of aging and attempt to develop preventative or rejuvenative strategies that better target multiple facets of this process.</p>","PeriodicalId":12202,"journal":{"name":"Experimental hematology","volume":" ","pages":"104698"},"PeriodicalIF":2.5,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The inhibitory receptor PVRIG is dominantly expressed in the bone marrow of patients with multiple myeloma and its blockade enhances T-cell engager's immune activation.

IF 2.5 4区医学

Experimental hematology Pub Date : 2024-12-16 DOI: 10.1016/j.exphem.2024.104696

Masha Frenkel, Zoya Alteber, Ning Xu, Mingjie Li, Haiming Chen, Deborah Hayoun, Roy Granit, Gady Cojocaru, James Berenson, Eran Ophir

引用次数: 0

Understanding Human Oncogene Function and Cooperativity in Myeloid Malignancy Using iPSCs.

IF 2.5 4区医学

Experimental hematology Pub Date : 2024-12-12 DOI: 10.1016/j.exphem.2024.104697

Martina Sarchi, Sergei Doulatov

引用次数: 0

RNA methylation: where to from here for hematologic malignancies?

IF 2.5 4区医学

Experimental hematology Pub Date : 2024-12-06 DOI: 10.1016/j.exphem.2024.104694

Andrew Adel Guirguis

{"title":"RNA methylation: where to from here for hematologic malignancies?","authors":"Andrew Adel Guirguis","doi":"10.1016/j.exphem.2024.104694","DOIUrl":"10.1016/j.exphem.2024.104694","url":null,"abstract":"<p><p>RNA methylation and the machinery that regulates or \"reads\" its expression has recently been implicated in the pathogenesis of acute myeloid leukemia (AML) and other hematologic malignancies. Modulation of these epigenetic marks has started to become a reality as several companies around the world seek to leverage this knowledge therapeutically in the clinic. Although the bases of observed activity in AML have been described by numerous groups, the exact context in which these therapies will ultimately be used remains to be properly determined. Although context is likely to be of great importance here, a more \"global\" mechanism of action might allow for more widespread applicability to multiple diseases or disease subtypes. In other areas such as the myelodysplastic and other preleukemic syndromes, data remain sparse. Ongoing work is needed to determine whether therapeutic modulation of RNA modifications is a viable and biologically plausible approach in these cases. Regardless of the outcomes, this is an exciting era for \"epitranscriptomics\" as we navigate a pathway forward. Here, I describe the current knowledge around RNA methylation and hematologic malignancies including some of the relevant questions that are yet to be answered.</p>","PeriodicalId":12202,"journal":{"name":"Experimental hematology","volume":" ","pages":"104694"},"PeriodicalIF":2.5,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nucleic acid metabolism: the key therapeutic target for myeloid tumors.

IF 2.5 4区医学

Experimental hematology Pub Date : 2024-12-06 DOI: 10.1016/j.exphem.2024.104693

Tomohiro Yabushita, Susumu Goyama

引用次数: 0

The developmental clock: where art and science meet.

IF 2.5 4区医学

Experimental hematology Pub Date : 2024-12-05 DOI: 10.1016/j.exphem.2024.104695

John D Crispino

引用次数: 0

IFC Editorial Board

IF 2.5 4区医学

Experimental hematology Pub Date : 2024-12-01 DOI: 10.1016/S0301-472X(24)00541-1

引用次数: 0

Cellular uptake of CPX-351 by scavenger receptor class B type 1–mediated nonendocytic pathway 细胞通过清道夫受体 B 类 1 型介导的非内皮细胞途径摄取 CPX-351。

IF 2.5 4区医学

Experimental hematology Pub Date : 2024-12-01 DOI: 10.1016/j.exphem.2024.104651

Hiroaki Araie, Naoko Hosono, Takahiro Yamauchi

{"title":"Cellular uptake of CPX-351 by scavenger receptor class B type 1–mediated nonendocytic pathway","authors":"Hiroaki Araie, Naoko Hosono, Takahiro Yamauchi","doi":"10.1016/j.exphem.2024.104651","DOIUrl":"10.1016/j.exphem.2024.104651","url":null,"abstract":"<div><div>The proper uptake of drugs in liposome formulations into target cells markedly impacts therapeutic efficacy. The protein corona (PC), formed by the adsorption of serum proteins onto the liposome surface, binds to specific surface receptors of target cells, influencing the uptake pathway. We investigated the uptake pathway into leukemia cells based on PC analysis of CPX-351, a liposome containing cytarabine and daunorubicin in a fixed 5:1 synergistic molar ratio. The PC of CPX-351 mixed with fetal bovine serum was analyzed by nanoflow liquid chromatography-tandem mass spectrometry. CPX-351 uptake in HL-60, K562, and THP-1 leukemia cell lines was measured by flow cytometry using daunorubicin fluorescence. The major components of CPX-351 PC include apolipoproteins A-I and A-II, which bind to scavenger receptor class B type 1 (SR-BI), a nonendocytic pathway that takes up only liposome contents. SR-BI was expressed in each cell, and its expression correlated with CPX-351 uptake. The uptake was significantly decreased by the inhibition of clathrin-mediated endocytosis and macropinocytosis. Additionally, blocks lipid transport-1 (BLT-1), a selective inhibitor of SR-BI, decreased the uptake; however, high-dose BLT-1 addition significantly increased the uptake, which was more strongly inhibited by macropinocytosis suppression compared with clathrin-mediated endocytosis. BLT-1 enhances the binding of SR-BI to liposomes in a dose-dependent manner. These findings indicate that the enhancement of binding between SR-BI and CPX-351 activates different pathways, such as macropinocytosis, distinct from CPX-351 alone. SR-BI may be a biomarker for CPX-351 therapy, and the combination of CPX-351 with high-dose BLT-1 may augment therapeutic efficacy.</div></div>","PeriodicalId":12202,"journal":{"name":"Experimental hematology","volume":"140 ","pages":"Article 104651"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0